US43906K1007 - Common Stock
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips HOOKIPA Pharma (NASDAQ:HOOK) just reported results for the fourth quarter of 20...
Best-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in...
NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
Hookipa (HOOK) stock fell 15% after the company said it was cutting 30% of its workforce amid news Roche had terminated a collaboration deal for the drug HB-700. Read more here.
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...
NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA Pharma files a prospectus for the proposed resale of 15M shares of common stock by a selling stockholder. This is not an offer to sell securities.
Polished.com stock is falling on Thursday as investors in POL react to the company's shares undergoing an extreme rally on Wednesday!
Brenmiller Energy stock is rising on Thursday as investors celebrate shares of BNRG regaining compliance with listing standards.
Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023,...
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for...
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+...
HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+...